Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early...

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

ProstACT Global Phase 3 study (part 1) achieves primary objectives

AstraZeneca initiates Phase 3 CLARITY-Gastric 02 trial of AZD0901 combo in CLDN18.2+ gastric cancer

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Fujifilm Invests in VALANX Biotech to Strengthen ADC CDMO Capabilities